In older adults, an AS01<sub>E</sub>-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease
Authors: Melina Awar, Eleftherios Mylonakis
Journal: Annals of Internal Medicine (2023)

ACP Journal ClubJune 2023In older adults, an AS01E-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract diseaseMelina Awar , MD, and Eleftherios Mylonakis , MDMelina Awar , MDHouston Methodist Hospital, Houston, Texas, USA (M.A., E.M.), and Eleftherios Mylonakis , MDHouston Methodist Hospital, Houston, Texas, USA (M.A., E.M.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/J23-0038 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationPapi A, Ison MG, Langley JM, et al; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388:595-608. https://pubmed.ncbi.nlm.nih.gov/36791160Clinical Impact RatingsGIM/FP/GP: GIM/FP/GP: Geriatrics: Infectious Disease: Pulmonology: Public Health: References1. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 1996;14:1214-1218. [PMID: 8961507] Google Scholar2. Food and Drug Administration. FDA briefing document: respiratory syncytial virus vaccine recombinant, adjuvanted (proposed trade name: Arexvy). Vaccines and Related Biological Products Advisory Committee meeting, 1 Mar 2023. Accessed at www.fda.gov/media/165622/download on 3 Apr 2023. Google Scholar3. Food and Drug Administration. FDA briefing document: respiratory syncytial virus vaccine (proposed trade name: Abrysvo). Vaccines and Related Biological Products Advisory Committee meeting, 28 Feb 2023. Accessed at www.fda.gov/media/165623/download on 3 Apr 2023. Google Scholar4. Walsh EE, Marc GP, Zareba AM, et al; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388:1465-1477. [PMID: 37018468] Google Scholar5. Goodman B. Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials. CNN. 29 Mar 2023. Accessed at www.cnn.com/2023/03/29/health/janssen-rsv-vaccine-trial/index.html on 11 Apr 2023. Google Scholar6. Van Effelterre T, Hens N, White LJ, et al. Modeling respiratory syncytial virus adult vaccination in the United States with a dynamic transmission model. Clin Infect Dis. 2023 Mar 23. [Epub ahead of print]. [PMID: 36949605] Google Scholar Author, Article, and Disclosure InformationAuthors: Melina Awar, MD; Eleftherios Mylonakis, MDAffiliations: Houston Methodist Hospital, Houston, Texas, USA (M.A., E.M.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=J23-0038.This article was published at Annals.org on 6 June 2023.ACP Journal Club is editorially independent from Annals of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoIn older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease Melina Awar , and Eleftherios Mylonakis In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease Melina Awar , and Eleftherios Mylonakis Metrics June 2023Volume 176, Issue 6Page: JC62KeywordsClinical trialsElderlyFood and Drug AdministrationPulmonary diseasesRespiratory syncytial virusRespiratory systemSafetySigns and symptomsUpper respiratory tract infectionsVaccines ePublished: 6 June 2023 Issue Published: June 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...